BioNTech says VEGF bispecific’s PD-L1 target, combo plans will be its edge

BioNTech said that its VEGF bispecific sets it apart from competitors because of its mechanism and how it plans to investigate the asset in combination with other modalities. During the German drugmaker’s third-quarter earnings call ...